Table 1.
WHO fungal priority pathogens list
| Pathogen | Final ranking of pathogens | Geographic distribution | Mortality |
|---|---|---|---|
| Critical priority group | |||
| Cryptococcus neoformans | 1 | Global | 41–61% |
| Candida auris | 2 | Global | 29–53% |
| Aspergillus fumigatus | 3 | Global | 47–88% |
| Candida albicans | 4 | Global | 20–50% |
| High priority group | |||
| Nakaseomyces glabrata (Candida glabrata) | 5 | Global | 20–50% |
| Histoplasma spp. | 6 | Global |
21–53% (HIV/AIDS patients) 9–11% (immunosuppressed patients) |
| Eumycetoma causative agents | 7 | Global | Lack of data. Thought to be low |
| Mucorales | 8 | Global |
23–80% (adult patients) 72.7% (pediatric patients) |
| Fusarium spp. | 9 | Global | 43–67% |
| Candida tropicalis | 10 | Global |
55–60% (adult patients) 26–40% (pediatric patients) |
| Candida parapsilosis | 11 | Global | 20–45% |
| Medium priority group | |||
| Scedosporium spp. | 12 | Global | 42–46% |
| Lomentospora prolificans | 13 | Global |
50–71% (adult patients) 50% (immunocompromised children) |
| Coccidioides spp. | 14 | Americas | 2–13% |
| Pichia kudriavzeveii (Candida krusei) | 15 | Global | 44–67% |
| Cryptococcus gattii | 16 | Global |
10–23% (CNS infections) 15–21% (pulmonary infections) |
| Talaromyces marneffei | 17 | South-East Asia, China | 12–21% |
| Pneumocystis jirovecii | 18 | Global | 0–100% |
| Paracoccidioides spp. | 19 | Central and South America | 3–23% |
Source WHO fungal priority pathogens list to guide research, development and public health action. CNS Central nervous system